Current immune–checkpoint blockade (ICB)-based immunotherapies, commonly targeting PD-1, PD-L1 and CTLA-4, have not achieved the desired efficacy in the therapeutic practices in different types of cancers, suggesting that tumor cells may develop other ways to evade immune surveillance. The gene discussed is CTLA4; the disease is neoplasm.